Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
A second H R antagonist with benzamide based structure
2022-08-31

A second H3R antagonist with benzamide-based structure from Johnson & Johnson is JNJ-31001074, known as Bavisant and under chemical IUPAC name of (4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone. It is a compound with molecular weight 329.44, HBA four, and MLogP 1.52 encompass
-
VEGFR Tyrosine Kinase Inhibitor II Hippo signaling is unique
2022-08-31

Hippo signaling is unique in that it does not possess a cognate ligand and receptor system. Instead, numerous upstream sensors that monitor cell morphology, cell polarity, cell-cell contact, and mechanical stress impinge onto the Hippo pathway core kinases, MST, and LATS. This in turn indicates the
-
br Acknowledgements and disclosures This
2022-08-31

Acknowledgements and disclosures This work was supported in part by the National Institutes of Health (R01 HL-131673-01A1) and the Veterans Administration (BX-002539-01), United States. The authors have nothing to disclose concerning any conflict of interest. Introduction Adaptations are ofte
-
Human immunodeficiency virus type HIV is responsible for
2022-08-31

Human immunodeficiency virus type 1 (HIV-1) is responsible for the 2×Taq PCR Master Mix(with dye) sale pandemic; notification is compulsory in Brazilian blood banks since 1988. From 1980 to 2016, the Brazilian MH reported 882,810 HIV/AIDS cases, with 52.3% in the southeast region. HIV/HCV co-infect
-
br Disclosure summary br Acknowledgments br Introduction Sym
2022-08-31

Disclosure summary Acknowledgments Introduction Symbionts are live microorganisms that seem to promote host defense systems and regulate intestinal homeostasis, preventing gut infectious and inflammatory diseases (Fuller, 1989, Sartor, 2004). Numerous studies have shown the beneficial effec
-
It is known that hypercapnia as
2022-08-29

It is known that hypercapnia, as well as hypoxia, can result in a decrease in body temperature, but the mechanisms involved are not very well known (Barros and Branco, 1998; Saiki and Mortola, 1996). One 832 582 4016 mg is that when there is an acute hypercapnic exposure, acidosis plays an inhibito
-
ONX-0914 A high fat maternal diet during the
2022-08-29

A high-fat maternal diet during the pregestation period and extending throughout gestation (including the period of conception) has the propensity of affecting early embryonic development and placentation. Previous investigations have revealed that the preimplantation embryos are generally exposed t
-
pd 0332991 sale However ghrelin has a short half life of min
2022-08-29

However, ghrelin has a short half-life of 15–20 min, because it is a natural peptide containing 28-amino acids, its clinical usefulness as a therapeutic agent may be limited (Mosińska et al., 2017; Vestergaard et al., 2007). Hence, many efforts have been made to elucidate the smallest segment of ghr
-
In our previous study we designed and
2022-08-26

In our previous study, we designed and synthesized compounds of A series from the starting material 4-hydroxy-3-methoxycinnamic graphpad molarity (ferulic acid). These compounds with R group being amino acid residues, fatty acyl group and sulfuryl group showed moderate HDAC inhibition and in vitro
-
Under increased drug pressure more protease variants with mo
2022-08-26

Under increased drug pressure, more protease variants with more than one substitution will likely become clinically relevant. The accumulation of additional substitutions can allow RAS variants to emerge that alone are not viable, but in combination can rescue the viral fitness. We previously demons
-
Another interesting approach is to use partial agonists
2022-08-26

Another interesting approach is to use partial agonists as starting point to develop specific antagonists like done in earlier decades [64], [65]. Possible indications for an attenuation of the NO/sGC signalling pathway might be specific neuronal disorders: an involvement in the aetiology of migrain
-
Dronedarone Glycogen synthase kinase GSK a
2022-08-26

Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase, has been confirmed to be involved in some biological processes in NaCl or wound-treated plants (Chen et al., 2003, Hai et al., 2001, Jonak et al., 2000). NO has been recently recognized as a vital signaling compound in plants. The NO don
-
siRNA construction and transfection For small
2022-08-26

siRNA construction and transfection. For small interfering RNA (siRNA) experiments, we used Stealth™ select RNAi oligonucleotides targeted against GPR120 (Gibco/Invitrogen). The target sequence of siGPR120 used were; sense 5′-AAGUGGGUGCGAUUGACUUGGUCCA-3′ and antisense 5′-UGGACCAAGUCAAUCGCACCCACUU-3′
-
br Conflict of Interest Both GM
2022-08-26

Conflict of Interest Both GM and BDH are shareholders in Caldan Therapeutics, a company exploring potential novel treatments for type 2 diabetes. Acknowledgments Work described herein was supported by Biotechnology and Biological Sciences Research Council [grant BB/K019864/1)] (to GM) and [gr
-
br Acknowledgements We thank the support of
2022-08-26

Acknowledgements We thank the support of the National Natural Science Foundation of China (NSFC) project 81501342 and support from the Disciplinary Group of Oncology and Immunology program of Xinxiang Medical University. Introduction First described as a new clinical entity in 1981, the Acqui
16657 records 419/1111 page Previous Next First page 上5页 416417418419420 下5页 Last page